natgillin/translations-raw huggingface dataset:
Imatinib Actavis 100 mg film-coated tablets 2 years 
Imatinib Actavis 100 mg filmom obložene tablete 2 godine
Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib (see section 4.5). 
U bolesnika u kojih je obavljena tireoidektomija i koji primaju nadomjesnu terapiju levotiroksinom zabilježeni su klinički slučajevi hipotireoze tijekom liječenja imatinibom (vidjeti dio 4.5).
DEX (6 mg/m2/day, PO): days 1-5; 29-33 
DEX (6 mg/m2/dan, p.o.): dani 1-5; 29-33
Hepatic failure8, hepatic necrosis 
Zatajenje jetre8, nekroza jetre
4 cycles 
Dodatna četiri
- Pain or swelling in your abdomen, flatulence, heartburn or constipation. 
- bol ili oticanje u trbuhu, vjetrovi, žgaravica ili zatvor. - svrbež.
How to take Imatinib Actavis 
Kako uzimati Imatinib Actavis
GI tumour sites may have been the source of the GI bleeds (see section 4.4). 
Uzrok GI krvarenja mogle bi biti lokacije GI tumora (vidjeti dio
Daunorubicin 30 mg/m2 i.v., days 1-3, 15-16; VCR 2 mg total dose i.v., days 1, 8, 15, 22; CP 750 mg/m2 i.v., days 1, 8; prednisone 60 mg/m2 oral, days 1-7, 15-21; IDA 9 mg/m2 oral, days 1-28; MTX 
Daunorubicin 30 mg/m2 i.v., dani 1-3, 15-16; VCR 2 mg ukupna doza i.v., dani 1, 8, 15, 22; CP 750 mg/m2 i.v., dani 1, 8; prednizon 60 mg/m2 peroralno, dani 1-7, 15-21; IDA 9 mg/m2 peroralno, dani 1-28;
Imatinib Actavis is also a treatment for children with CML. 
Actavis se kod djece također koristi za liječenje KML-a.
Laboratory test abnormalities 
Abnormalne vrijednosti laboratorijskih testova Hematologija
Tumour haemorrhage/tumour necrosis* 
Tumorsko krvarenje/tumorska nekroza*
Printing ink: shellac glaze-45%, black iron oxide (E172), propylene glycol, ammonium Hydroxide 28%. 
Tinta za označavanje: šelak glazura-45%, crni željezov oksid (E172), propilenglikol, amonijev hidroksid 28%.
- Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph-positive ALL). 
- Akutne limfoblastične leukemije s pozitivnim Philadelphia kromosomom (Ph-pozitivni ALL).
EU/1/13/825/015 10 tablets EU/1/13/825/016 30 tablets EU/1/13/825/017 60 tablets EU/1/13/825/018 90 tablets 
EU/1/13/825/015 10 tableta EU/1/13/825/016 30 tableta EU/1/13/825/017 60 tableta EU/1/13/825/018 90 tableta
Thrombocythaemia, lymphopenia, bone marrow depression, eosinophilia, lymphadenopathy 
Trombocitemija, limfopenija, depresija koštane srži, eozinofilija, limfadenopatija
Ileus/intestinal obstruction*, gastrointestinal perforation*, diverticulitis*, gastric antral vascular ectasia (GAVE)* 
Ileus/intestinalna opstrukcija*, gastrointestinalna perforacija*, divertikulitis*,
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and acute lymphoblastic leukaemia (ALL) patients. 
Abl pozitivnim staničnim linijama, kao i u svježim leukemijskim stanicama osoba koje boluju od kronične mijeloične leukemije (KML) s pozitivnim Philadelphia kromosomom i od akutne limfoblastične leukemije (ALL).
The dose is 800 mg per day (2 capsules), to be taken as one capsule in the morning and a second capsule in the evening. 
Doza je 800 mg na dan (2 kapsule), koja se uzima kao jedna kapsula ujutro i druga kapsula navečer.
Posology for MDS/MPD The recommended dose of imatinib is 400 mg/day for adult patients with MDS/MPD. 
Za odrasle bolesnike s MDS/MPD-om preporučena doza imatiniba iznosi 400 mg/dan.
Tablet coat 
bol u kostima10
Imatinib Actavis 400 mg film-coated tablets 21 month 
Imatinib Actavis 400 mg filmom obložene tablete 21 mjesec
Flatulence, abdominal distension, gastro-oesophageal reflux, constipation, dry mouth, gastritis 
Flatulencija, abdominalna distenzija, gastroezofagealni refluks, konstipacija,
EU/1/13/825/008 10 tablets EU/1/13/825/009 20 tablets EU/1/13/825/010 30 tablets EU/1/13/825/011 60 tablets EU/1/13/825/012 90 tablets EU/1/13/825/013 120 tablets EU/1/13/825/014 180 tablets 
EU/1/13/825/008 10 tableta EU/1/13/825/009 20 tableta EU/1/13/825/010 30 tableta EU/1/13/825/011 60 tableta EU/1/13/825/012 90 tableta EU/1/13/825/013 120 tableta EU/1/13/825/014 180 tableta
If your daily dose is 800 mg (2 tablets), you should take one tablet in the morning and a second in the evening. 
Ako Vaša dnevna doza iznosi 800 mg (2 tablete), trebate uzimati jednu tabletu ujutro i drugu navečer.
EU/1/13/825/020 10 capsules EU/1/13/825/021 30 capsules EU/1/13/825/022 60 capsules EU/1/13/825/023 90 capsules 
EU/1/13/825/020 10 kapsula EU/1/13/825/021 30 kapsula EU/1/13/825/022 60 kapsula EU/1/13/825/023 90 kapsula
CPM (250 mg/m2/dose q12h x 4 doses, IV): days 3 and 4 PEG-ASP (2500 IUnits/m2, IM): day 4 
CPM (250 mg/m2/doza svakih 12 sati x 4 doze, i.v.): dani 3 i 4 PEG-ASP (2500 IU/m2, i.m.): dan 4
If your daily dose is 800 mg (8 tablets), you should take 4 tablets in the morning and 4 tablets in the evening. 
Ako Vaša dnevna doza iznosi 800 mg (8 tableta), trebate uzimati 4 tablete ujutro i 4 tablete navečer.
Each film-coated tablet contains 0.75 mg lecithin (soya) (E322) For the full list of excipients, see section 6.1. 
Svaka filmom obložena tableta sadrži 0,75 mg sojinog lecitina (E322)
Complete blood counts must be performed regularly during therapy with imatinib. 
Laboratorijske pretrage Tijekom terapije imatinibom mora se redovito kontrolirati kompletna krvna slika.
Newly diagnosed Ph+ ALL: In a controlled study (ADE10) of imatinib versus chemotherapy induction in 55 newly diagnosed patients aged 55 years and over, imatinib used as single agent induced a significantly higher rate of complete haematological response than chemotherapy (96.3% vs. 50%; 
Novodijagnosticirani Ph+ ALL: u kontroliranom ispitivanju (ADE10) imatiniba u odnosu na kemoterapiju u 55 novodijagnosticiranih bolesnika u dobi od 55 godina i više, imatinib korišten samostalno izazvao je značajno višu stopu potpunog hematološkog odgovora nego kemoterapija
Caution should be taken when administering imatinib with inhibitors of the CYP3A4 family. 
Kada se imatinib primjenjuje s inhibitorima porodice CYP3A4, potrebno je oprezno postupati.
- Joint pain with swelling. 
- bolovi u zglobovima s oticanjem.
The usual starting dose is 600 mg to be taken as one capsule of 400 mg plus 2 capsules of 100 mg once a day. 
Uobičajena početna doza je 600 mg, koja se uzima kao jedna kapsula od 400 mg plus 2 kapsule od 100 mg jednom na dan.
Shellac Glaze-45% Black iron oxide (E172) Propylene glycol Ammonium Hydroxide 28% 
Tinta za označavanje šelak glazura-45% željezov oksid, crni (E172) propilenglikol amonijev hidroksid 28%
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially ‘sodium-free'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po filmom obloženoj tableti, tj. zanemarive količine natrija.
In GIST the study drug was discontinued for drug-related adverse reactions in 4% of patients. 
U ispitivanju GIST-a, primjena ispitivanog lijeka je prekinuta u 4% bolesnika zbog nuspojava povezanih s njegovom primjenom.
(0.5 h), days 7, 8, 14, 15; CP 500 mg/m2 i.v. 
8 mg/m i.v. (0,5 h), dani 7, 8, 14, 15; CP 500 mg/m i.v.(1 h) dan 1; Ara
VP-16 (100 mg/m2/day, IV): days 22-26 
VP-16 (100 mg/m2/dan, i.v.): dani 22-26
(1 h) day 1; AraC 60 mg/m2 i.v., days 22-25, 29-32 
C 60 mg/m2 i.v., dani 22-25, 29-32
1200 to 1600 mg (duration varying between 1 to 10 days): Nausea, vomiting, diarrhoea, rash, erythema, oedema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite. 
1200 do 1600 mg (trajanje je variralo između jednog i 10 dana): mučnina, povraćanje, proljev, osip,
Active substances that may have their plasma concentration altered by imatinib: 
Djelatne tvari čije bi koncentracije u plazmi imatinib mogao promijeniti:
Posology for DFSP The recommended dose of imatinib is 800 mg/day for adult patients with DFSP. 
Doziranje za DFSP Za odrasle bolesnike s DFSP-om preporučena doza imatiniba iznosi 800 mg/dan.
Five (5) patients with DFSP and PDGFR gene re-arrangements were reported in 3 publications. 
U 3 publikacije zabilježeno je pet (5) bolesnika s DFSP-om i preraspodjelom PDGFR gena.
There was no change in the kinetics of imatinib on repeated dosing, and accumulation was 1.5-2.5-fold at steady state when dosed once daily. 
Nije bilo promjene kinetike imatiniba nakon ponovljenog doziranja, a akumulacija je bila
- Feeling sick (nausea) with diarrhoea and vomiting, abdominal pain or fever (signs of bowel problems). 
- mučnina s proljevom i povraćanjem, bol u trbuhu ili vrućica (znakovi crijevnih problema).
Renal failure chronic 
Pedijatrijska kronična faza
If your daily dose is 800 mg (2 capsules), you should take one capsule in the morning and a second capsule in the evening. 
Ako Vaša dnevna doza iznosi 800 mg (2 kapsule), trebate uzimati jednu kapsulu ujutro i drugu kapsulu navečer.
When the response rate is calculated from patients with at least one valid assessment, the response rate for CHR, CCyR and MR was 20/22 (90.9%), 9/9 (100%) and 11/17 (64.7%), respectively. 
20/22 (90,9%), 9/9 (100%) odnosno 11/17 (64,7%).
Organ function impairment 
Oštećenje funkcije organa
Oval-shape, 18.6x6.6 mm, biconvex dark yellow to brownish film-coated tablet, embossed with company logo on one side and “37” with score line on the other side. 
Ovalna, bikonveksna filmom obložena tableta, veličine 18,6x6,6 mm, tamnožute do smeđe boje s utisnutim logom tvrtke na jednoj strani i „37“ s razdjelnom crtom na drugoj strani.
The same publication reported long term follow-up data from 12 MDS/MPD patients with PDGFR gene rearrangements (5 patients from study B2225). 
Ista publikacija je objavila i podatke dugotrajnog praćenja od 12 MDS/MPD bolesnika s preraspodjelom
Induction therapy I DEX 10 mg/m2 oral, days 1-5; VCR 2 mg i.v., days 6, 13, 20; daunorubicin 45 mg/m2 i.v., days 6-7, 13-14 
I DEX 10 mg/m2 peroralno, dani 1-5; VCR 2 mg i.v., dani 6, 13, 20; daunorubicin 45 mg/m2 i.v., dani 6-7, 13-14
At the time of analysis, the treatment duration was a median of 47 months (24 days - 60 months). 
47 mjeseci (24 dana - 60 mjeseci).
Hard capsule with light yellow cap and light yellow body imprinted with 50 mg in black ink. 
Tvrda kapsula sa svijetložutom kapicom i svijetložutim tijelom sa crnom tintom otisnutim natpisom 50 mg.
Hard capsule of size 00 with orange opaque colour cap and body imprinted with “400 mg” in black ink. 
Tvrda kapsula veličine 00 s narančastom i neprozirnom kapicom i tijelom s oznakom „400 mg“
Migraine, somnolence, syncope, peripheral neuropathy, memory impairment, sciatica, restless leg syndrome, tremor, cerebral haemorrhage 
Migrena, pospanost, sinkopa, periferna neuropatija, poremećaj pamćenja,
See section 4. 
PRILOG II.
aANC < 0.5 x 109/L and/or platelets < 10 x 109/L 
aABN <0,5 x 109/l i/ili trombociti <10 x 109/l
Mild 
Blagi
Fluid retention and oedema, fatigue 
Retencija tekućine i edem, umor
These patients received imatinib for a median of 47 months (range 24 days - 60 months). 
Ti su bolesnici primali imatinib za medijan od 47 mjeseci
Imatinib Actavis 50 mg hard capsules Imatinib Actavis 100 mg hard capsules Imatinib Actavis 400 mg hard capsules 
Imatinib Actavis 50 mg tvrde kapsule Imatinib Actavis 100 mg tvrde kapsule Imatinib Actavis 400 mg tvrde kapsule
Imatinib Actavis 400 mg film-coated tablets EU/1/13/825/015 
Imatinib Actavis 400 mg filmom obložene tablete EU/1/13/825/015
ANC < 1.0 x 109/L and/or platelets < 50 x 109/L 
ABN <1,0 x 109/l i/ili trombociti <50 x 109/l
Evaluation by a cardiology specialist, performance of an echocardiogram and determination of serum troponin should therefore be considered in patients with HES/CEL, and in patients with MDS/MPD associated with high eosinophil levels before imatinib is administered. 
Prije primjene imatiniba u bolesnika s HES/KELom i u bolesnika s MDS/MPD-om povezanim s visokim razinama eozinofila potrebno je razmisliti o pregledu kod specijaliste kardiologa, obavljanje ehokardiograma i određivanje serumskog troponina.
CPM (300 mg/m2/day, IV): days 22-26 
CPM (300 mg/m2/dan, i.v.): dani 22-26
Imatinib Actavis 100 mg film-coated tablets EU/1/13/825/008 
Imatinib Actavis 100 mg filmom obložene tablete EU/1/13/825/008
The recommended starting dose is 600 mg to be taken as one tablet of 400 mg plus 2 tablets of 100 mg once a day. 
Preporučena početna doza je 600 mg, koja se uzima kao jedna tableta od 400 mg i 2 tablete od 100 mg jednom na dan.
Lecithin (soya) 
Sojin lecitin
- Chronic renal failure. 
- kronično zatajanje bubrega.
Posology for HES/CEL The recommended dose of imatinib is 100 mg/day for adult patients with HES/CEL. 
Za odrasle bolesnike s HES/KEL-om preporučena doza imatiniba iznosi 100 mg/dan.
Imatinib Actavis 100 mg film-coated tablets Imatinib Actavis 400 mg film-coated tablets 
Imatinib Actavis 100 mg filmom obložene tablete Imatinib Actavis 400 mg filmom obložene tablete
Imatinib Actavis 400 mg hard capsules Each hard capsule contains 400 mg imatinib (as mesilate). 
Imatinib Actavis 400 mg tvrde kapsule Svaka tvrda kapsula sadrži 400 mg imatiniba (u obliku imatinibmesilata).
If your daily dose is 800 mg (16 capsules), you should take 8 capsules in the morning and 8 capsules in the evening. 
Ako Vaša dnevna doza iznosi 800 mg (16 kapsula), trebate uzimati 8 kapsula ujutro i 8 kapsula navečer.
of the dose was recovered within 7 days in faeces (68% of dose) and urine (13% of dose). 
Na temelju izlučivanja spoja(eva) nakon oralne, pomoću 14C- označene doze imatiniba, oko 81% doze izlučilo se u roku od 7 dana u stolici (68% doze) i mokraći (13% doze).
Hard capsule of size 3 with light yellow cap and light yellow body imprinted with “50 mg” in black ink. 
Tvrda kapsula veličine 3 sa svijetložutom kapicom i svijetložutim tijelom s oznakom "50 mg"
Iron oxide yellow (E172) Titanium dioxide (E171) Iron oxide red (E172) Lecithin (soya) (E322) Xanthan gum (E415) 
Ovojnica tablete poli(vinilni alkohol), djelomično hidrolizirani talk željezov oksid, žuti (E172) titanijev dioksid (E171) željezov oksid, crveni (E172) sojin lecitin (E322) ksantanska guma (E415)
9 Musculoskeletal pain during treatment with imatinib or after discontinuation has been observed in post-marketing. 
9 Nakon stavljanja lijeka u promet primijećena je mišićno-koštana bol koja se javlja tijekom liječenja imatinibom, kao i nakon prekida liječenja.
- Pelvic pain sometimes with nausea and vomiting, with unexpected vaginal bleeding, feeling dizzy or fainting due to low blood pressure (signs of problems with your ovaries or womb). 
omaglica ili nesvjestica zbog sniženog krvnog tlaka (znakovi problema s jajnicima ili maternicom).
This medicine contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially ‘sodium-free'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po tvrdoj kapsuli, tj. zanemarive količine natrija.
Imatinib Actavis 400 mg tablets imatinib 
Imatinib Actavis 400 mg tablete imatinib
Imatinib Actavis 50 mg hard capsules Each hard capsule contains 50 mg imatinib (as mesilate). 
Imatinib Actavis 50 mg tvrde kapsule Svaka tvrda kapsula sadrži 50 mg imatiniba (u obliku imatinibmesilata).
Remission induction DEX 10 mg/m2 oral, days 6-7, 13-16; VCR 1 mg i.v., days 7, 14; IDA 8 mg/m2 i.v. 
Indukcija remisije DEX 10 mg/m2 peroralno, dani 6-7, 13-16; VCR 1 mg i.v., dani 7, 14; IDA
This medicinal product contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially ‘sodium-free'. 
Natrij Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po tvrdoj kapsuli, tj. zanemarive količine natrija.
In the event of recurrence of ANC < 1.0 x 109/L and/or platelets < 50 x 109/L, repeat step 1 and resume imatinib at reduced dose of 260 mg/m2. 
<1,0 x 109/l i/ili trombociti <50 x 109/l, treba ponoviti 1. korak i nastaviti primjenu imatiniba u smanjenoj dozi od 260 mg/m2
Imatinib Actavis 50 mg hard capsules EU/1/13/825/001 
Imatinib Actavis 50 mg tvrde kapsule EU/1/13/825/001
How to store Imatinib Actavis 
Kako čuvati Imatinib Actavis
Hard capsule with light orange cap and light orange body imprinted with 100 mg in black ink. 
Tvrda kapsula sa svijetlonarančastom kapicom i svijetlonarančastim tijelom sa crnom tintom otisnutim natpisom 100 mg.
Ear and labyrinth disorders 
Poremećaji uha i labirinta Manje često
The starting dose is 100 mg, to be taken as one capsule of 100 mg once a day. 
Početna doza je 100 mg, koja se uzima kao jedna kapsula od 100 mg jednom na dan.
Imatinib Actavis 400 mg hard capsules EU/1/13/825/020 
Imatinib Actavis 400 mg tvrde kapsule EU/1/13/825/020
Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, indicating an inhibition of the CYP3A4 by imatinib. 
Imatinib povećava srednju vrijednost Cmax i AUC simvastatina (CYP3A4 supstrat) za 2, odnosno
Stop imatinib until ANC ≥ 1.5 x 109/L and platelets ≥ 75 x 10 
Ukinuti imatinib sve dok ABN ne bude ≥1,5 x 109/l i trombociti ≥75 x
The starting dose is 400 mg to be taken as 4 capsules once a day. 
Početna doza je 400 mg, koja se uzima kao 4 kapsule jednom na dan.
Package leaflet: Information for the user Imatinib Actavis 100 mg film-coated tablets imatinib 
Uputa o lijeku: Informacije za bolesnika Imatinib Actavis 100 mg filmom obložene tablete imatinib
Headache2 
Glavobolja2
DEX 10 mg/m2 oral, days 1-5; CP 200 mg/m2 i.v., days 3, 4, 5; MTX 12 mg intrathecal, day 1 
DEX 10 mg/m2 peroralno, dani 1-5; CP 200 mg/m2 i.v., dani 3, 4, 5; MTX 12 mg intratekalno, dan 1
Joint and muscle stiffness 
Ukočenost zglobova i mišića
LIST OF EXCIPIENTS PHARMACEUTICAL FORM AND CONTENTS 
PRILOG I SAŽETAK OPISA SVOJSTAVA LIJEKA
Reproductive system and breast disorders 
Poremećaji reproduktivnog sustava i dojki Manje često
Package leaflet: Information for the user Imatinib Actavis 400 mg film-coated tablets imatinib 
Uputa o lijeku: Informacije za bolesnika Imatinib Actavis 400 mg filmom obložene tablete imatinib
The starting dose is 100 mg, to be taken as one tablet of 100 mg once a day. 
Početna doza je 100 mg, koja se uzima kao jedna tableta od 100 mg jednom na dan.
If your daily dose is 800 mg (8 capsules), you should take 4 capsules in the morning and 4 capsules in the evening. 
Ako Vaša dnevna doza iznosi 800 mg (8 kapsula), trebate uzimati 4 kapsule ujutro i 4 kapsule navečer.
Imatinib Actavis 100 mg tablets imatinib 
Imatinib Actavis 100 mg tablete imatinib
The starting dose is 100 mg, to be taken as 2 capsules once a day. 
Početna doza je 100 mg, koja se uzima kao 2 kapsule jednom na dan.
- Mouth ulcers. 
- čirevi u ustima.
DFSP (at dose 800 mg) ANC < 1.0 x 109/L and/or platelets < 50 x 109/L 
KML-a i blastična kriza (početna doza 340 mg/m aABN <0,5 x 109/l i/ili trombociti <10 x 109/l
and/or platelets < 10 x 109/L 
9/l i/ili trombociti <50 x 109/l
Stop imatinib until ANC ≥ 1.5 x 109/L and platelets ≥ 75 x 109/L. 
Ukinuti imatinib sve dok ABN ne bude ≥1,5 x 109/l i/ili trombociti ≥75 x 109/l
DEX 10 mg/m2 oral, days 1-5; CP 200 mg/m2 i.v., days 3-5; MTX 15 mg intrathecal, day 1 
DEX 10 mg/m2 peroralno, dani 1-5; CP 200 mg/m2 i.v., dani 3-5; MTX 15 mg intratekalno, dan 1
- Numb or cold toes and fingers (signs of Raynaud's syndrome). 
- utrnuli ili hladni prsti na nogama i rukama (znakovi Raynaudovog sindroma). - iznenadno oticanje i crvenilo kože (znakovi kožne infekcije zvane celulitis). - oslabljen sluh.
If you are unable to swallow the tablets, you can dissolve them in a glass of still or mineral water or apple juice: - Use about 50 ml for each 100 mg tablet. 
Ako ne možete progutati tabletu, možete je otopiti u čaši obične ili mineralne vode ili soka od jabuke:
The usual starting dose is 600 mg to be taken as 6 tablets once a day. 
Uobičajena početna doza je 600 mg, koja se uzima kao 6 tableta jednom na dan.
Concomitant use of imatinib and medicinal products that induce CYP3A4 (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or Hypericum perforatum, also known as St. John's Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure. 
Istodobna primjena imatiniba i lijekova koji induciraju CYP3A4 (npr. deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital ili Hypericum perforatum, poznat također kao gospina trava)
Your doctor may decide to increase the dose to 400 mg, to be taken as one capsule of 400 mg once a day, depending on how you respond to treatment. 
Ovisno o tome kako reagirate na liječenje, liječnik može odlučiti povećati dozu do 400 mg, koja se uzima kao jedna kapsula od 400 mg jednom na dan.
Hypokalaemia, increased appetite, hypophosphataemia, decreased appetite, dehydration, gout, hyperuricaemia, hypercalcaemia, hyperglycaemia, hyponatraemia 
Hipokalijemija, povećan apetit, hipofosfatemija, smanjen apetit, dehidracija,
Round, 9.2 mm in diameter, biconvex dark yellow to brownish film-coated tablet, embossed with company logo on one side and “36” with score line on the other side. 
Okrugla, bikonveksna filmom obložena tableta promjera 9,2 mm, tamnožute do smeđe boje s utisnutim logom tvrtke na jednoj strani i „36“ s razdjelnom crtom na drugoj strani.
The usual starting dose is 600 mg to be taken as 12 capsules once a day. 
Uobičajena početna doza je 600 mg, koja se uzima kao 12 kapsula jednom na dan.
Imatinib Actavis 100 mg hard capsules EU/1/13/825/003 
Imatinib Actavis 100 mg tvrde kapsule EU/1/13/825/003
Imatinib Actavis 50 mg capsules imatinib 
Imatinib Actavis 50 mg kapsule imatinib
- if you experience bruising, bleeding, fever, fatigue and confusion when taking Imatinib Actavis, contact your doctor. 
Prije početka liječenja liječnik će pažljivo pregledati bolesnike radi utvrđivanja eventualnih znakova te infekcije. ako dobijete modrice, krvarenje, vrućicu, umor i smetenost prilikom uzimanja Imatiniba Actavis, kontaktirajte liječnika.
- Feeling light-headed, dizzy or fainting (signs of low blood pressure). 
- osjećaj da Vam se vrti u glavi, omaglica ili nesvjestica (znakovi sniženog krvnog tlaka).
Blood and lymphatic system disorders 
Anafilaktički šok* Poremećaji krvi i limfnog sustava Vrlo često
Imatinib Actavis 100 mg hard capsules Each hard capsule contains 100 mg imatinib (as mesilate). 
Imatinib Actavis 100 mg tvrde kapsule Svaka tvrda kapsula sadrži 100 mg imatiniba (u obliku imatinibmesilata).
The starting dose is 100 mg, to be taken as one tablet once a day. 
Početna doza je 100 mg, koja se uzima kao jedna tableta jednom na dan.
(1 h), days 1-5; VM26 60 mg/m2 i.v. 
Ara-C 75 mg/m2 i.v. (1 h), dani 1-5; VM26 60 mg/m2 i.v. (1 h), dani 1-5
(1 h), days 28-31, 35-38, 42-45; 6-MP 60 mg/m2 oral, days 26-46 
CP 1 g/m2 i.v. (1 h), dani 26, 46; Ara-C 75 mg/m2 i.v. (1 h), dani 28-31, 35-38, 42-45; 6-MP 60 mg/m2 peroralno, dani 26-46
Your doctor may decide to increase the dose to 400 mg, to be taken as one tablet of 400 mg once a day, depending on how you respond to treatment. 
Ovisno o tome kako reagirate na liječenje, liječnik može odlučiti povećati dozu do 400 mg, koja se uzima kao jedna tableta od 400 mg jednom na dan.
VCR (1.5 mg/m2/day, IV): days 1, 8 and 15 
VCR (1,5 mg/m2/dan, i.v.): dani 1, 8 i 15
VCR (1.5 mg/m2/day, IV): days 1, 8, and 15 
VCR (1,5 mg/m2/dan, i.v.): dani 1, 8, i 15
Clinical studies in chronic myeloid leukaemia 
Klinička ispitivanja kod HES/KEL-a
As cardiac adverse events have been reported uncommonly with imatinib, a careful assessment of the benefit/risk of imatinib therapy should be considered in the HES/CEL population before treatment initiation. 
Budući da su srčane nuspojave zabilježene manje često uz imatinib, prije početka liječenja u HES/KEL
If laboratory or clinical findings associated with TMA occur in a patient receiving Imatinib Actavis, treatment should be discontinued and thorough evaluation for TMA, including ADAMTS13 activity and antiADAMTS13-antibody determination, should be completed. 
Ako se laboratorijski ili klinički nalaz povezan s TMA-om javi u bolesnika koji prima Imatinib Actavis,
Uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people): - Chest pain, irregular heart rhythm (signs of heart problems). 
Manje česte (mogu se javiti u do 1 na 100 osoba) ili rijetke (mogu se javiti u do 1 na 1000 osoba):
Each film-coated tablet contains 100 mg of imatinib (as mesilate). 
Svaka filmom obložena tableta sadrži 100 mg imatiniba (u obliku imatinibmesilata).